AccessibilityHelpAbout Us
Medicure logo

Medicure(OTC) MCUJF

Market Cap$20.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-92%
5 Year+144%
1 Year+173%
1 Month+111%
$1.93
+4.20%
+0.08Today
Medicure last closing stock price
MetricPriceDate
Last closeUSD 1.932026-09-17
Medicure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.99%USD 1.892026-09-10
1 month+110.68%USD 0.922026-08-14
3 month+185.75%USD 0.672026-06-17
Year to date+141.05%USD 0.802025-12-31
1 year+173.24%USD 0.712025-09-16
3 year+76.85%USD 1.092023-09-12
5 year+144.01%USD 0.792021-09-16
Since inception-91.97%USD 24.002004-02-17

Medicure Financials at a Glance

Market Cap

$20.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$32.09M

Net Income (TTM)

-CA$7.45M

EPS (TTM)

-$0.51

P/E Ratio

-3.75

Dividend

$0.00

Beta (Volatility)

0.02 (Low)

Price

$1.93

Volume

12,500

Open

$1.86

Previous Close

$1.93

Daily Range

$1.86 - $1.93

52-Week Range

$0.67 - $1.93

Estimated Earnings Date

Nov 19, 2026

MCUJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicure

Medicure Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for the cardiovascular market, primarily in Canada and the United States. The company offers a range of products, including AGGRASTAT, ZYPITAMAG, and ReDS, aimed at addressing critical cardiovascular conditions.

Products and Services
  • AGGRASTAT injection for managing acute coronary syndrome
  • ZYPITAMAG for treating primary hyperlipidemia
  • ReDS, a non-invasive device for measuring lung fluid
Growth Outlook
  • Recent quarterly revenue reached CAD 7.43 million, showing potential for growth
  • Strong product pipeline targeting cardiovascular health needs
  • Expansion into online distribution channels enhances market reach
Financial Highlights
  • Trailing twelve months revenue of CAD 30.5 million, indicating steady demand
  • Gross profit margin improved to 43% in the latest quarter
  • Operating cash flow of CAD 386,000 in Q2 2026, reflecting operational efficiency
Medicure Inc. operates in the specialized drug manufacturing sector, focusing on cardiovascular treatments. The company has established a solid foundation with its key products, which address significant health issues. The recent quarterly revenue indicates a positive trend, suggesting that the company is well-positioned for future growth. The improvement in gross profit margin and positive operating cash flow further highlight operational efficiencies and potential profitability. With a focus on expanding its product offerings and distribution channels, Medicure Inc. presents an intriguing opportunity for investors interested in the biopharmaceutical sector.
AI Generated • Aug 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

Albert D. Friesen, PhD

Website

www.medicure.com

Headquarters

Winnipeg, MB R3T 6C6, CA

MCUJF Financials

Key Financial Metrics (TTM)

Gross Margin

38.00%

Operating Margin

-22.62%

Net Income Margin

-23.23%

Return on Equity

-54.73%

Return on Capital

-49.91%

Return on Assets

-32.98%

Earnings Yield

-26.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.44M

Volume

12.50K

Avg. Volume

5.17K

Financials (TTM)

Gross Profit

CA$12.20M

Operating Income

-CA$7.25M

EBITDA

-CA$4.49M

Operating Cash Flow

-CA$1.93M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$1.93M

Cash & ST Invst.

CA$1.83M

Total Debt

CA$696.00K

Medicure Performance Analysis

Medicure annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 17,717,0472.2%
20232023-12-31CAD 16,073,357-9.3%
20242024-12-31CAD 15,990,959-0.5%
20252025-12-31CAD 20,650,70929.1%
Medicure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3022.3%
Q42025-12-314.6%
Q12026-03-31-6.7%
Q22026-06-30-6.8%
Medicure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.10N/A
20232023-12-31CAD -0.07N/A
20242024-12-31CAD -0.0711.0%
20252025-12-31CAD -0.49569.5%
Medicure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-62.5%
Q42025-12-31-207.7%
Q12026-03-3190.3%
Q22026-06-30-259.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$7.43M

+11.4%

Gross Profit

CA$3.20M

-6.9%

Gross Margin

43.06%

N/A

Market Cap

$20.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$874.70K

N/A

Employees

23

N/A

Net Income

-CA$1.43M

-81.7%

EBITDA

-CA$577.00K

-912.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$1.83M

-61.3%

Total Debt

CA$696.00K

-36.3%

Accounts Receivable

CA$4.73M

-7.0%

Inventory

CA$3.51M

-12.3%

Long Term Debt

CA$269.00K

-56.0%

Short Term Debt

CA$427.00K

-11.2%

Return on Assets

-32.98%

N/A

Return on Invested Capital

-61.27%

N/A

Free Cash Flow

CA$386.00K

+152.9%

Operating Cash Flow

CA$386.00K

+152.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRRTFCrescita Therapeutics, Inc.
$0.56+0.00%
TRUFFRhelion Life Sciences Corp.
$0.02-0.83%
UNVCUnivec, Inc.
$0.00+9.00%
OILFFNextleaf Solutions Ltd.
$0.03+4.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.99-10.22%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$114.82+10.44%
CRWVCoreWeave
$79.88-4.16%
NOKNokia
$10.60+4.54%

Questions About MCUJF

What is the current price of Medicure?

Medicure is trading at $1.93 per share.

What is the 52-week range for Medicure?

Over the past 52 weeks, Medicure has traded between $0.67 and $1.93.

How much debt does Medicure have?

As of the most recent reporting period, Medicure reported total debt of CA$490.57K.

How much cash does Medicure have on hand?

Medicure reported CA$1.29M in cash and cash equivalents in its most recent financial results.

What is Medicure’s dividend yield?

Medicure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services